Bharat Biotech is in the middle of conducting a phase 3 trial with 22,000 subjects.
In the study, the scientists assessed the effects of the drug in two types of animal hearts, and found that it altered the timing of electrical waves that control heartbeat.
Named after 'Feluda', the detective character in legendary filmmaker Satyajit Ray's stories, the test has been developed by Debojyoti Chakraborty and Souvik Maiti as a simpler way of detecting SARS-coV2 presence in clinical samples, IGIB Director Anurag Agarwal said.
Both manufacturers have sought funds in excess of Rs 150 crore under the department of biotechnology's Mission Covid Suraksha scheme. Announced last November, the scheme has an outlay of Rs 900 crore to help develop Covid vaccines, from the clinical development stage to setting up production sites.
The test kit has the advantage of testing 90 samples together in a single run of 2.5 hours, so that healthcare professionals can proceed quickly with necessary next steps.
There are a number of vaccine candidates already in clinical trial and a few out of those candidates have completed phase 1/2 status, he said, adding that there are trials that will be going into phase three sometime at the end of July and then others will follow in the months of August, September and October.
Investment bankers said retail investors were pulling back, while institutions were being pickier
Studies in China claim that traditional Chinese medicines seem to be working effectively on patients with mild or moderate symptoms of coronavirus.
Experts said the strain has not propelled a surge in cases like Omicron, but advised strict adherence to COVID-19-appropriate behaviour.
When a person gets an infection even after being vaccinated against it, it is called a breakthrough case.
Commercial launch and supply to major government and private hospitals is expected in mid-June.
According to the World Health Organisation, 10 candidate vaccines for COVID-19 are in the clinical evaluation and 126 are in the pre-clinical stage.
By 2022, there is a plan to make an mRNA-technology vaccine, for which it has tied up with Canadian firm Providence Therapeutics.
The vaccine would be first made available to the vulnerable population and eventually, it would be available in the private market for all.
Sharma was the president of the conference, the first since the Paris Agreement of COP21 that expected parties to make enhanced commitments towards mitigating climate change.
The company claimed that the AYUSH ministry has "categorically agreed" that Patanjali had "appropriately worked on COVID-19 management".
Addressing a press briefing, health ministry Joint Secretary Lav Agarwal said currently there are no approved therapies for COVID-19 and there is not enough evidence to claim that plasma therapy can be used for treatment of the disease.
"The licence for the drug was obtained on the basis of the traditional knowledge and experience related to the medicinal virtues of Ashwagandha, Giloy and Tulsi," Patanjali spokesperson S K Tijarawala said.
There is a process to be followed for EUL and pre-qualification of vaccines under which a company has to complete phase 3 trials and submit the whole data to the regulatory department of WHO which is examined by an expert advisory group," Swaminathan said.
'The deaths of the children in the Gambia would batter India's reputation as the developing world's pharmacy.'
India has purchased 500 million doses of the Oxford University-AstraZeneca vaccine candidate, one billion from the United States company Novavax and 100 million doses of the Sputnik V candidate from Russia's Gamaleya Research Institute, according to the US-based Duke University Global Health Innovation Center.
As the global debate on booster shots gathers momentum, several scientists in New Delhi said the priority must be to ensure that more people are inoculated with at least their first jab.
'I can say with confidence that any future SARS-CoV-2 vaccine, developed anywhere in the world, would have to be manufactured in India, if it is to be affordable and of high quality.'
Mu -- also known by its scientific name as B.1.621 -- was first identified in Colombia in January 2021, and since then, there have been 'sporadic reports' of cases and some larger outbreaks in South America and Europe, the United Nations health agency said in its weekly bulletin on the pandemic on Tuesday.
According to these experts, a monkeypox outbreak can effectively be tackled by strong surveillance.
India's COVID-19 recovery rate rose to 63.13 per cent on Wednesday with a record 28,472 patients recuperating from the disease in 24 hours, while the case fatality rate further dropped to 2.41 per cent, the Union health ministry said.
What the UK is getting out of the Serum Institute is what India is losing. And the responsibility of the Indian State ought to have been to dictate where Serum Institute's vaccine doses should go, argues Ambassador M K Bhadrakumar.
Sputnik V is the third vaccine India has given the go-ahead to after 'Covishield', developed by Oxford University and AstraZeneca and 'Covaxin', the indigenous vaccine manufactured by Bharat Biotech. Covishield is manufactured by the Serum Institute of India.
"I think we'll have a vaccine by the end of the year," Trump said at a Fox News virtual town hall. "We'll have a vaccine much sooner rather than later."
Anti-inflammatory or immunomodulatory therapy, such as steroids, can have the risk of secondary infection like invasive mucormycosis, when used too early, at higher dose or for longer than required, they highlighted.
'Even if Serum Institute and Bharat Biotech were successful in ramping up production overnight, what happens to the capacity after the demand from India is met?' asks Sanjeev Nayyar.
The renowned pulmonologist, who was part of the national COVID task force, highlighted the need for research on developing vaccines which will cover not only the current circulating strains but also from the emerging variants.
The interim findings of the trial in which the four drugs were tested in 405 hospitals across 30 countries, covering 11,266 adults, were released on 'medRxiv', a preprint server, on Thursday. The findings are under review for publication in a medical journal.
While some researchers are developing prototypes for ventilators to overcome their shortage, others have teamed up to develop testing kits.
To increase focus on hiring people from diverse skillset
This doctor couple put their faith in India. And in return India has put faith in them.
'The lockdown was for both: To flatten the curve or more correctly, delay the rapid spread of COVID outbreak, and to create healthcare infrastructure.'
'Several concerns were raised with respect to the veracity of the data and analyses conducted by Surgisphere Corporation and its founder'
The researchers found that after being exposed to high levels of the novel coronavirus, none of the six monkeys that were given the vaccine developed viral pneumonia. Also, there was no sign that the vaccine had made the animals more vulnerable.
Following a six-day schedule, reducing class size, setting up isolation facilities on campus, and COVID-19 screening of students, faculty and staff are among the guidelines announced by the University Grants Commission (UGC) for reopening of universities and colleges closed since March in view of the pandemic.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances